Background {#Sec1}
==========

Rheumatoid arthritis (RA) is a severe chronic inflammatory joint disease that can lead to joint damage and functional impairment. Early therapy with disease-modifying anti-rheumatic drugs (DMARDs) can improve outcomes and limit joint damage and irreversible loss of physical function \[[@CR1]--[@CR3]\]. With the advent of newer therapeutic agents and treatment strategies \[[@CR4], [@CR5]\], the goal of remission is achievable in a proportion of patients \[[@CR6]--[@CR8]\]. Importantly, patients in clinical remission usually do not accrue additional joint damage \[[@CR9], [@CR10]\]. Despite these benefits of early therapy, drug-free remission is not attainable in the majority of patients \[[@CR11], [@CR12]\].

Early in the course of RA, a unique stage called the "window of opportunity" may exist. During this stage, key steps in pathogenesis may be reversible, with DMARD therapy blocking progression to full disease manifestations and potentially leading to sustained remission \[[@CR13], [@CR14]\]. Several findings provide support for the window of opportunity hypothesis: an increase in the risk of persistent disease after several months of arthritis symptoms \[[@CR15], [@CR16]\]; differences in immunological abnormalities in very early compared with established disease \[[@CR17], [@CR18]\]; and the ability of early treatment with a tumour necrosis factor (TNF) inhibitor plus methotrexate (MTX) to allow some patients with RA to achieve a drug-free remission \[[@CR19], [@CR20]\]. Information on the existence of the window of opportunity on the basis of current data is limited, however, since some studies did not have a double-blind design, evaluated only a very small number of patients and/or were performed only in a single centre. Furthermore, recent data obtained in patients with early disease suggest that, in those fulfilling the classification criteria of RA, drug-free remission after such induction therapy may be uncommon \[[@CR12], [@CR21]\].

Very little is known about the pathogenic processes operative in very early inflammatory arthritis, especially in those subjects who do not meet the classification criteria of RA \[[@CR17], [@CR18], [@CR22]\]. Since remission due to MTX therapy alone is rare \[[@CR23]\], we reasoned that MTX monotherapy might not be sufficient to induce lasting remission, even at this early stage of disease. Moreover, even though the presence of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) has been found to identify subjects at increased risk of progressing to RA \[[@CR24]\], we elected not to limit entry to subjects that had developed these biomarkers, but rather to examine a broader group of subjects who had developed unexplained inflammatory arthritis within the past 3 months in order to determine whether the presence of these antibodies or even the classification of RA altered the likelihood of progressing to RA despite intense therapy. The goal of this study, therefore, was to determine whether intense therapy with MTX plus infliximab (IFX) compared with MTX alone or placebo had the capacity to induce long-lasting drug-free remission in subjects with a very short period of inflammatory arthritis symptoms who had not received prior DMARD therapy.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

The Definitive Intervention in New Onset Rheumatoid Arthritis (DINORA) study was a double-blind, randomised, placebo-controlled, multi-centre, investigator-initiated trial of the effects of anti-TNFα chimeric monoclonal antibody IFX in combination with MTX in patients with very early inflammatory arthritis and was conducted at 14 rheumatology centres across Europe (three in Austria, four in the Netherlands, four in Germany, and one each in Greece, Italy, and Spain). The study design is depicted in Additional file [1](#MOESM1){ref-type="media"}: Figure SA. The trial was registered at <http://www.isrctn.com/ISRCTN21272423>. Patient recruitment started in October 2007 and ended in February 2012. The study was conducted in accordance with the Declaration of Helsinki. Ethical committees of each institution approved the study and all patients gave written informed consent.

Patients and randomisation {#Sec4}
--------------------------

Patients were eligible for the trial if they had symptom duration of 2 to 12 weeks and had synovial swelling present in at least two joints (66 joint count); at least one joint must have been a metacarpophalangeal, proximal interphalangeal, or metatarsophalangeal (MTP) joint; MTP joints only were considered insufficient for inclusion. Baseline visits were scheduled if clinical joint swelling (arthritis) by history was present for 12 weeks and confirmed at two pre-treatment visits between week 2 and week 12 (Additional file [1](#MOESM1){ref-type="media"}: Figure SA). Patients with a positive purified protein derivative (PPD) test or chest radiograph performed at screening suggesting tuberculosis, malignancy, chronic infectious disease, elevated liver enzymes, or patients who were pregnant or planning to become pregnant within 6 months after the last infusion were excluded. Furthermore, patients with a distinct diagnosis made after a routine diagnostic work-up, such as a connective tissue disease, psoriatic arthritis, gout, pseudogout, reactive arthritis, or parvovirus arthritis, were not eligible. Thus, only patients with undifferentiated arthritis or early RA \[[@CR25]\] were enrolled in the trial.

Procedures of the study {#Sec5}
-----------------------

Patients were randomised into three groups in a 2:2:1 ratio by a computer generated randomisation list to infliximab plus methotrexate (IFX + MTX), MTX monotherapy (MTX), or placebo (PL). For randomisation, patients were stratified for the use of glucocorticoids (users versus non-users, see below) and the presence of ACPA (\> 7 units, measured by enzyme-linked immunosorbent assay (ELISA)) or high titre RF (\> 50 IU/ml by nephelometry), determined in a central laboratory. Local investigators were blinded to the results of the central RF and ACPA testing and were also discouraged from having these tests performed on site. For reasons of blinding, a "double-dummy-like" administration of study medication was pursued. Every patient was treated with tablets containing MTX or PL and with infusions containing IFX or PL. The study medication code was kept blinded in patients who discontinued prematurely. Patients were followed until week 106. For rescue therapy for patients who discontinued treatment, the protocol recommended leflunomide (20 mg daily without a loading dose) or sulfasalazine (up to 3000 mg/day) with or without low-dose glucocorticoids.

Patients received treatment with IFX + MTX, MTX alone, or PL. In addition, supportive therapy appropriate at this early stage of arthritis was allowed in all three treatment groups. This therapy included non-steroidal anti-inflammatory drugs and, if necessary, glucocorticoids at a dose of no more than 10 mg/day prednisone or equivalent. MTX was dosed orally according to a rapid dose escalation scheme: treatment was started at 10 mg/week and increased to 25 mg/week in three steps with 2-week intervals except in cases of intolerance. IFX was administered by intravenous infusions at a dose of 3 mg/kg at 0, 2, and 6 weeks, and at 5 mg/kg every 8 weeks thereafter (and thus at higher than the minimal dose approved for maintenance therapy).

All core set variables were assessed at every visit. These variables included swollen and tender joint counts (SJC and TJC; using a 66- and 68-joint count, respectively), patient and evaluator global assessments (PGA and EGA, on a 100-mm visual analogue scale (VAS)), patient pain assessment (by VAS), erythrocyte sedimentation rate (ESR; mm/h), C-reactive protein (CRP; mg/dl), American College of Rheumatology (ACR) 20, 50, and 70% response rates \[[@CR26]\], and the Health Assessment Questionnaire Disability Index (HAQ) \[[@CR27]\]. Furthermore, composite measures of disease activity, such as Clinical and Simplified Disease Activity Index (CDAI and SDAI) \[[@CR28]\] and Disease Activity Score 28 (DAS28) using 28-joint counts and ESR \[[@CR29]\] were calculated.

Radiographs of hands and feet were taken at baseline, 6 months, 1 year, and 2 years and scored independently using the Sharp-van-der-Heijde (SvdH) method \[[@CR30]\] by two readers who were blinded to patient characteristics and group allocation but who were aware of the chronological order of the films. The joint space narrowing (JSN) and erosion scores as well as their sum, representing the total score, were evaluated. The average score of the two readers was used for the analyses. In addition, random-effects models were fitted with and without imputation and by taking into account the scores from both readers and the interaction between treatment allocation and study visit to assess if the rate of radiological progression between the three treatment groups was significantly different.

Endpoints {#Sec6}
---------

Persistent clinical remission at weeks 46 and 54 compared between all three treatment groups was taken as the primary endpoint. Clinical remission was defined as follows: at two consecutive visits, no swollen joint (66-joint count), 0 to at most 2 tender joints (68-joint count but counting unilateral MTPs as one joint), and a CRP level within the normal range (\< 0.5 mg/dl) or a normal ESR (\< 25 mm/h). At the time of the study design, the ACR/European League Against Rheumatism (EULAR) remission criteria \[[@CR26]\] had not yet been developed. The criteria chosen here, however, are consistent with these criteria; similar to the Boolean or index-based remission criteria, they do not allow for more than two affected joints (sum of swollen or tender) and require a normal CRP \[[@CR10], [@CR28]\].

In all patients, the last infusion of IFX was planned at week 54 (or earlier, as specified below), whereas MTX was continued at the same dose until week 58 and then tapered in all patients over 4 weeks (weekly reduction by 5 mg/week, last dose at week 62). IFX + MTX, MTX, or PL was discontinued earlier if clinical remission was attained at two consecutive visits after the 14-week visit. Thus, for patients who reached clinical remission at two or more consecutive visits before week 54 (sustained remission), IFX (or PL) was stopped and MTX (or PL) tapered beginning after the second visit in remission (first planned possible IFX withdrawal at week 30; Additional file [1](#MOESM1){ref-type="media"}: Figure SA). Since the patients would not know on which regimen they had achieved remission, no blinded infusions were continued from that time-point onward. However, as mentioned above, to qualify for the primary endpoint, patients had to have sustained remission until week 54 irrespective of early withdrawal. The study was continued until week 106 without further study medication to evaluate long-term maintenance of remission; blinding of initial treatment assignment remained intact.

Statistical analysis {#Sec7}
--------------------

The sample size calculation is described in Additional file [2:](#MOESM2){ref-type="media"} Supplement S1. Descriptive statistics were used for baseline characteristics and demographic data. We applied a strategy of step-wise hierarchical hypothesis testing \[[@CR31]\] to control for type I error of the primary and key secondary (SDAI and DAS28 scores) endpoints. The primary endpoint was analysed at the fixed 46- to 54-week time point (because two visits were needed to define sustained/persistent remission) using Fisher's exact test. Persistent clinical remission at weeks 46 and 54 was evaluated as a categorical variable (in remission or not) and Fisher's exact test was calculated for differences over all three treatment groups. For the primary endpoint analysis, we applied non-responder imputation (NRI) for dichotomous variables from those visits onward at which patients had missing data or for patients who started rescue DMARD therapy, and the last observation carried forward (LOCF) method for continuous variables. In case of a significant result regarding the overall difference between all three groups, the primary endpoint was subsequently assessed comparing each of two groups, respectively: group 1 (IFX + MTX) versus 3 (PL), 1 (IFX + MTX) versus 2 (MTX), and 2 (MTX) versus 3 (PL). Longitudinal data analysis of clinical remission is described in Additional file [2:](#MOESM2){ref-type="media"} Supplement S2. Secondary endpoints were tested at years 1 and 2 using either Fisher's exact test for categorical variables or Kruskal-Wallis test for continuous data.

Results {#Sec8}
=======

Demographic data and patient flow {#Sec9}
---------------------------------

Of the 122 screened patients, 90 were randomised and dosed at the baseline visit (Fig. [1](#Fig1){ref-type="fig"}). Baseline characteristics and demographic data are described in Table [1](#Tab1){ref-type="table"}. Table [2](#Tab2){ref-type="table"} depicts the number of patients in clinical remission in the three treatment groups at 6 months, 1 year, and 2 years. Early withdrawal within the first 3 months was seen in three patients in the IFX + MTX group , in two in the MTX group, and in one patient in the PL group.Fig. 1Patient flow chart; the patient flow of the DINORA study. BL baseline, MTX methotrexate, PPD purified protein derivative, SAE serious adverse eventTable 1Baseline characteristics of the study sampleIFX + MTXMTXPL*P* valueNumber of patients (*n*)3836160.4440Female26 (68.4%)28 (77.8%)9 (56.3%)0.2833Age (years), mean ± SD52.1 ± 14.152.9 ± 14.054.4 ± 11.20.9170Symptom duration (weeks)^a^, mean ± SD10.3 ± 2.39.4 ± 2.39.8 ± 1.80.0722Rheumatoid factor positive13 (34.2%)13 (36.1%)7 (43.8%)0.7988Patients who used steroids prior to the study24 (63.2%)22 (61.1%)9 (56.3%)0.8931Anti-citrullinated protein antibody positive18 (47.4%)16 (44.4%)7 (43.8%)0.9563Patients who meet the ACR/EULAR 2010 classification criteria for RA, 2010 \[[@CR25]\]26 (68%)19 (53%)12 (75%)0.2135Patients who meet the 1987 ARA classification criteria for RA \[[@CR35]\]22 (58%)19 (53%)9 (56%)0.9049Health Assessment Questionnaire (0--3)0.9 ± 0.70.9 ± 0.60.7 ± 0.70.2903Disease Activity Score 28 (DAS28; based on ESR)5.0 ± 1.44.8 ± 1.34.7 ± 1.10.8464Simplified Disease Activity Index (SDAI)34.3 ± 23.831.1 ± 14.427.5 ± 20.00.4771Clinical Disease Activity Index (CDAI)25.1 ± 14.726.2 ± 13.923.5 ± 11.90.8951Swollen joint count (0--28)7.2 ± 5.76.50 ± 5.17.4 ± 4.60.7048Tender joint count (0--28)9.2 ± 7.310.3 ± 7.27.8 ± 5.60.5263Visual analogue scale pain (mm)44.0 ± 29.344.2 ± 24.344.6 ± 22.70.9595Patient global assessment (mm)48.6 ± 29.047.8 ± 24.739.6 ± 21.00.5274Evaluator/physician global assessment (mm)38.6 ± 18.346.3 ± 22.344.6 ± 20.70.3627C-reactive protein (mg/dl)1.71 ± 2.401.18 ± 1.880.98 ± 1.280.5567Erythrocyte sedimentation rate (ESR; mm/h)23.2 ± 20.320.3 ± 21.220.4 ± 12.60.8129Total Sharp-van-der-Heide score2.8 ± 5.43 ± 3.84.6 ± 8.60.4816Erosion score1.2 ± 1.81.6 ± 2.22.2 ± 4.20.6019Joint space narrowing score1.6 ± 3.81.4 ± 2.22.4 ± 4.40.5658Data are shown as mean ± standard deviation or *n* (%) as appropriateThe parameters showed no significant differences between the three groups at baselineTables with additional data on baseline characteristics as well as 1-year data for the patients who were in remission at 1 year are provided in Additional file [2](#MOESM2){ref-type="media"} (Tables SC and SD)*ACR* American College of Rheumatology, *ARA* American Rheumatism Association, *EULAR* European League Against Rheumatism, *IFX* infliximab, *MTX* methotrexate, *PL* placebo, *RA* rheumatoid arthritis^a^Symptom duration refers to the first visit when the patients presented themselves at the centres. At the baseline visit, symptom duration of all patients was 12 weeks because baseline visits were scheduled at this time to ensure persistent arthritis for 12 weeks. Patients who had no residual arthritis at the baseline visit were excludedTable 2Clinical characteristics of the study sample at 6 months, 1 year, and 2 yearsIFX + MTX\
*n* = 38MTX\
*n* = 36PL\
*n* = 16Clinical remission (primary endpoint), no. of patients in remission (%) 6 months10 (26%)6 (17%)0 1 year12 (32%)5 (14%)0 2 years9 (24%)1 (3%)3 (19%)Other definitions of remission, no. of patients in remission (%) Disease Activity Score 28 (DAS28)  6 months20 (53%)11 (31%)1 (6%)  1 year24 (63%)13 (36%)3 (19%)  2 years23 (61%)11 (31%)5 (31%) Simplified Disease Activity Index (SDAI)  6 months16 (42%)9 (25%)1 (6%)  1 year18 (47%)13 (36%)1 (6%)  2 years18 (47%)13 (36%)4 (25%) ACR/EULAR Boolean  6 months15 (40%)8 (22%)0  1 year13 (34%)9 (25%)1 (6%)  2 years13 (34%)10 (28%)4 (25%) ACR improvement, responders  ACR20   6 months20 (53%)18 (50%)4 (25%)   1 year22 (58%)22 (61%)3 (19%)   2 years19 (50%)19 (53%)3 (19%)  ACR50   6 months16 (42%)13 (36%)1 (6%)   1 year17 (45%)16 (44%)3 (19%)   2 years14 (37%)15 (42%)3 (19%)  ACR70   6 months15 (40%)6 (17%)1 (6%)   1 year14 (37%)11 (31%)2 (13%)   2 years13 (34%)11 (31%)3 (19%)Other secondary outcome parameters (mean ± SD) Pain  6 months17.3 ± 20.322.5 ± 25.242.7 ± 31.0  1 year20.9 ± 23.818.3 ± 25.345.7 ± 31.8  2 years23.0 ± 25.123.3 ± 29.843.5 ± 32.8 Swollen joints (28 joints)  6 months2.3 ± 5.22.1 ± 4.54.9 ± 5.6  1 year2.3 ± 5.22.1 ± 4.35.0 ± 5.6  2 years2.8 ± 5.62.4 ± 4.55.1 ± 5.6 Tender joints (28 joints)  6 months2.9 ± 5.94.9 ± 6.27.0 ± 6.4  1 year2.5 ± 5.64.2 ± 6.07.2 ± 6.8  2 years3.4 ± 6.54.0 ± 6.17.1 ± 7.0 Patient global visual analogue scale (VAS; mm)  6 months17.7 ± 6.523.1 ± 24.635.1 ± 28.2  1 year21.2 ± 24.018.4 ± 24.738.0 ± 29.3  2 years24.3 ± 25.324.8 ± 30.035.6 ± 29.5 Evaluator global VAS (mm)  6 months16.1 ± 22.017.2 ± 24.134.6 ± 28.0  1 year14.1 ± 20.817.7 ± 24.639.3 ± 29.8  2 years16.6 ± 24.118.4 ± 24.734.5 ± 31.3 C-reactive protein (mg/dl)  6 months0.5 ± 0.90.6 ± 1.00.8 ± 0.9  1 year0.5 ± 0.90.5 ± 1.00.7 ± 0.8  2 years0.6 ± 1.10.6 ± 1.00.5 ± 0.8 Erythrocyte sedimentation rate (mm)  6 months14.6 ± 12.217.8 ± 12.514.9 ± 6.9  1 year14.6 ± 12.318.7 ± 13.018.3 ± 9.7  2 years16.5 ± 14.117.6 ± 11.216.5 ± 10.7 Health Assessment Questionnaire (HAQ)  6 months0.30 ± 0.450.57 ± 0.640.54 ± 0.67  1 year0.33 ± 0.460.52 ± 0.620.61 ± 0.66  2 years0.41 ± 0.520.58 ± 0.610.62 ± 0.65 X-rays^a^  6 months−0.02 ± 0.880.07 ± 0.230.41 ± 1.53  1 year0.18 ± 1.060.16 ± 0.440.0 ± 0.41  2 years0.36 ± 0.950.28 ± 0.670.63 ± 1.31Missing data for continuous variables were imputed using last observation carried forward (LOCF). LOCF was also applied from the time points onwards when patients received other DMARDs as rescue therapy. The denominator for the percentages given is the number of patients initially included in each group and stays consistent for each year*ACR* American College of Rheumatology, *EULAR* European League Against Rheumatism, *IFX* infliximab, *MTX* methotrexate, *PL* placebo^a^Mean change of scores ± SD from baseline of Sharp-van-der-Heijde (SvdH) for patients with complete follow-up data at each time point

Clinical remission at 1 year {#Sec10}
----------------------------

At week 54 (primary endpoint), more patients in the IFX + MTX group (12/38, 32%) achieved sustained clinical remission compared with 5/36 (14%) on MTX alone and none (0/16, 0%) on PL. The overall difference across all three treatment groups showed statistical significance (*p* \< 0.05; Additional file [1](#MOESM1){ref-type="media"}: Figure SB). Upon subsequent pairwise comparisons, differences in rates of sustained clinical remission were significant between IFX + MTX and PL (treatment effect: 32%; *p* \< 0.05), but not between the IFX + MTX and MTX (treatment effect 18%; *p* \> 0.05), nor between MTX and PL (treatment effect 14%; *p* \> 0.05). Figure [2](#Fig2){ref-type="fig"} shows sustained remission rates as defined for the primary outcome in a cumulative way over time for each of the treatment groups. By week 30, 10 patients (26%) treated with IFX + MTX had already achieved clinical remission at two consecutive visits and all these patients sustained clinical remission until weeks 46 and 54. It is noteworthy that almost one in three patients receiving IFX + MTX, but only one in seven in the MTX group and none on PL had achieved sustained clinical remission at 1 year. The number needed to treat (NNT) to achieve one additional sustained remission at 52 weeks with IFX + MTX was 3 compared with placebo, while the NNT for MTX alone versus placebo was 7; NNT was 6 when comparing IFX + MTX with MTX alone. The results of the longitudinal data analysis are described in Additional file [2:](#MOESM2){ref-type="media"} Supplement S3.Fig. 2Proportions of remissions; percentage of patients who achieved remission for each time point across the treatment groups. The denominator stays constant, meaning for example in the infliximab (IFX) + methotrexate (MTX) group that the proportion of patients in remission is always divided by 38 (the total number of patients included in this group at baseline). PL placebo

Clinical remission at the end of year 2 {#Sec11}
---------------------------------------

Maintenance of a remission state until the end of year 2 differed significantly across the three groups (*p* = 0.0210); only 20% of patients in remission on MTX monotherapy at 54 weeks maintained remission, whereas this was the case in 75% of those attaining this state on IFX + MTX despite withdrawal of therapy (*p* = 0.0140 for the comparison between IFX + MTX and MTX groups; Table [2](#Tab2){ref-type="table"}). The NNT to achieve sustained remission at 2 years with IFX + MTX was 2 compared with treatment with MTX alone, and 2 compared with placebo; the NNT for MTX alone versus placebo was 5.

Changes in disease activity and core set variables {#Sec12}
--------------------------------------------------

At week 54, the proportions of patients with DAS28 \< 2.6 and ACR20 responses were significantly different over all three groups (*p* \< 0.01 for DAS28 \< 2.6 and *p* \< 0.05 for ACR20), as well as pain scores measured on a VAS (*p* \< 0.05). The stratified differences between treatment groups revealed significance between the IFX + MTX and MTX groups (*p* \< 0.05 for DAS28 \< 2.6), IFX + MTX and PL (*p* \< 0.001 for DAS28 \< 2.6; *p* \< 0.05 for ACR20; *p* \< 0.05 for pain scores), and between MTX and PL (*p* \< 0.01 for ACR20; *p* \< 0.01 for pain scores).

Patients classified as RA or non-RA at baseline {#Sec13}
-----------------------------------------------

In the IFX + MTX group, 8/26 (30.8%) of the patients classified as RA \[[@CR25]\] achieved clinical remission at the primary endpoint (1 year) compared with 4/12 (33.3%) of the patients who did not fulfil RA classification criteria. In the MTX group, 2/19 (10.5%) of the patients classified as RA reached the primary endpoint at 1 year compared with 3/17 (17.6%) of the patients who did not fulfil RA criteria (data not shown). When looking at the 2-year outcome in the IFX + MTX group, 5/26 (19%) of the patients classified as RA \[[@CR25]\] achieved clinical remission compared with 4/12 (33.3%) of the patients who did not fulfil RA classification criteria. In the MTX group, 1/19 (5%) patient classified as RA reached the remission at 2 years compared with none who did not fulfil RA criteria (data not shown). Two of the three patients who were in remission after 2 years in the PL group fulfilled the RA classification criteria at baseline, and all three PL patients were ACPA and RF negative. Thus, there was no difference in outcomes whether patients fulfilled the ACR/EULAR classification criteria \[[@CR25]\] or not. The presence of RF made a significant difference in the remission frequency at the 2-year time only point (Chi square test; *p* = 0.0399); the presence of ACPA made no significant difference in the frequency of remission at 6 months, 1 year, or 2 years.

Radiographic changes {#Sec14}
--------------------

Mean change from baseline of the Sharp-van-der-Heide scores \[[@CR30]\] did not reveal any noteworthy differences between the three treatment groups (Table [2](#Tab2){ref-type="table"} and Additional file [2](#MOESM2){ref-type="media"}: Figure SC and Table SA).

Adverse events {#Sec15}
--------------

The occurrences of adverse events (AEs) and serious adverse events (SAEs) are depicted in Table [3](#Tab3){ref-type="table"}. There were no statistically significant differences in the number of patients with AEs between the three treatment groups (Fisher's exact test; data not shown).Table 3Patients with adverse events (AEs) and serious adverse events (SAEs)Total\
*n* = 90IFX + MTX\
*n* = 38MTX\
*n* = 36PL\
*n* = 16Adverse events, *n* (%) Infectious/parasitic disease31 (35%)19 (50%)9 (25%)3 (19%) Malignancy1 (1%)01 (3%)0 Disease of blood, blood-forming organs, and immune mechanisms (except arthritis)1 (1%)1 (3%)00 Endocrine, nutritional, and metabolic diseases9 (10%)2 (5%)5 (14%)2 (12%) Disease of the nervous system17 (19%)6 (16%)9 (25%)2 (13%) Diseases of the eye3 (3%)1 (3%)2 (6%)0 Diseases of circulatory system16 (18%)6 (16%)7 (19%)3 (19%) Diseases of respiratory system43 (48%)23 (61%)16 (44%)4 (25%) Diseases of the digestive system37 (41%)15 (39%)17 (47%)5 (31%) Diseases of the skin and subcutaneous tissue25 (28%)12 (32%)8 (22%)5 (31%) Diseases of musculoskeletal system and connective tissue30 (33%)15 (39%)9 (25%)6 (38%) Diseases of urogenital system (pregnancy, childbirth, and puerperium)4 (4%)2 (5%)2 (6%)0 Symptoms, signs, and abnormal clinical and laboratory findings not elsewhere classified27 (30%)11 (29%)11 (31%)5 (31%) Injury, poisoning and certain other consequences of external causes9 (10%)6 (16%)3 (8%)0 External causes of morbidity1 (1%)1 (3%)00 Total1209935SAEs (*n* = 12) Hospitalisation due to different reasons^a^413 Fainted during blood collection prior to administration of study drug100 Significantly raised transaminase levels100 Hematuria, followed by a diagnosis of bladder cancer010 Hypertensive episode 1 h after the last infusion with study drug010Only 4 (0.9%) of all reported AEs and no SAEs were considered definitely related to the study drug. 155 AEs (37%) and no SAEs were regarded as possibly/probably related to one of the study drugs. No participant died during the 2-year study period. Two SAEs were related to infections (1 gastrointestinal, 1 genitourinary); however, in both cases patients were on PL only. One of these SAEs was related to a malignancy (bladder cancer on MTX monotherapy) and none to tuberculosis*IFX* infliximab, *MTX* methotrexate, *PL* placebo^a^Hyperglycemia (PL), diarrhoea (PL), urinary tract infection (IFX + MTX), urinary tract infection with fever (PL), MTX pneumonitis (opportunistic) infection (IFX + MTX), significant flare of disease activity (IFX + MTX), myocardial infarction more than half a year after last study drug (MTX), and biliary pancreatitis in a time after the study medication (IFX + MTX)

Discussion {#Sec16}
==========

The present trial in patients with very early arthritis yields several important findings on the effects of treatment of early inflammatory arthritis with DMARD therapy. First, as in the SAVE trial \[[@CR32]\], our study indicated that spontaneous remission (on placebo and supportive treatment alone) occurred only very rarely in patients with undifferentiated arthritis or very early RA of 12 weeks duration. Secondly, we observed that therapy with anti-TNF plus MTX, while significantly different from PL regarding all outcomes, produced more than twice as many stringently defined remissions when compared with MTX alone (32% and 14%, respectively); while the trend was clear, the difference in response rates did not achieve statistical significance (*p* = 0.10). Thirdly, we found that the majority of those patients who had remission on IFX + MTX therapy maintained remission even after withdrawal of all therapies (overall 24% still had clinical remission at 2 years); in contrast, 80% of those on MTX alone lost their remission state, leaving only 3% of MTX-treated patients in remission at 2 years. Fourthly, the vast majority of patients who achieved sustained drug-free remission had already attained this state within 30 weeks, indicating that the necessity for longer treatment durations to achieve remission does not increase drug-free remission rates. Together, these findings suggest that once joint inflammation is clinically manifest, symptomatic therapy does not impact on the course of disease, that initiation of DMARD therapy is warranted to improve outcomes, and that early intensive treatment with anti-TNF + MTX leads to drug-free remission in 1 of 4 patients. When we assessed other remission definitions, such as SDAI or Boolean remission criteria or DAS28 \< 2.6, we saw even higher remission rates in the IFX + MTX group at 1 year (34--63%), but this was also the case for the MTX group and the difference across all three groups was not significant, except for DAS28 \< 2.6. These findings might be due to the heterogeneity of the patients in our study; furthermore, our data suggest that aggressive therapy is not always necessary in very early inflammatory arthritis for obtaining sustained drug-free remission, although we did not find any respective predictive markers (data not shown).

In addition to delineating the effects of DMARD therapy on early inflammatory arthritis, this study provides important new information on the validity of the window of opportunity hypothesis. This hypothesis proposes that a short period of intensive therapy early in the disease course may reverse the disease process and produce long-term benefits. Indeed, in this study, almost one-third of the patients receiving IFX + MTX achieved sustained remission, with 9/12 (75%) of those who attained remission in the first year maintaining this state 1 year later without any treatment (or a total of 9/38 (24%) of the randomised patients). This outcome contrasts with that of patients treated with MTX alone since only 1 in 7 achieved remission in the first year, with the majority subsequently losing this state; as a result, only 3% of patients treated with MTX alone had a sustained remission at 2 years. Thus, anti-TNF + MTX induction treatment demonstrated a clear advantage compared with supportive therapy at 1 year and compared with MTX-only therapy at 2 years; in contrast, induction with MTX alone failed to show a significantly better response than placebo. Importantly, the active therapies, in particular anti-TNF plus MTX, did not appear to cause major serious adverse events in this early arthritis patient population, with the two observed serious adverse events occurring in patients on supportive care.

While one-third of patients treated with IFX + MTX had a favourable outcome, two-thirds of the patients treated with these agents did not attain remission within the first year. This result is disappointing and could argue against the window of opportunity hypothesis. It is important to note, however, that our results pertain only to the combination of IFX + MTX. As shown in other studies, RA patients can differ in their response to biological agents, perhaps based on their mode of action, and we do not know which patients will respond best to a given targeted therapy \[[@CR33]\]. On the other hand, the study outcome is quite promising, since 1 of 4 patients with early arthritis did reach drug-free remission after a short course of an induction therapy with these agents. Importantly, in contrast to other randomised controlled trials in early, although established, RA, we did not observe a gradual decline in responders over the second year \[[@CR21], [@CR34]\], suggesting a true abrogation or reversal of the disease process.

Our study has several limitations. First, the study may have been underpowered to show a significant difference between the IFX + MTX and MTX-alone groups. For the purposes of this study, we estimated placebo and spontaneous remission rates on the basis of previous observational studies, and the lack of precise data on remission rates from these trials could have led to difficulties in balancing MTX alone and anti-TNF + MTX responses. Although our results indicate that the majority of patients failed to achieve sustained remission on anti-TNF + MTX, the difference between anti-TNF + MTX and MTX alone in the first year might have reached statistical significance with a larger sample size. Of note, in this regard, patients treated with MTX alone did not maintain remission until the end of year 2 while IFX + MTX patients did, suggesting relevant differences in the effects of combination therapy compared with monotherapy. The results of our study need to be interpreted with caution; however, they do suggest that early intensive treatment may alter the course of inflammatory arthritis. One notable unexpected finding was the difficulty of recruiting patients into this study which contrasted with our experience from a previous study \[[@CR32]\]. We attempted to enrol very early arthritis patients who had to consent to their participation in a long-term (2 years) study at one of their first visits to the rheumatology centre before many of them had the opportunity to recognise and accept the implications of a diagnosis of inflammatory arthritis and possibly RA. Our experiences may be useful in planning future investigator-driven studies with larger sample sizes in this very early arthritis population of patients.

Conclusions {#Sec17}
===========

In conclusion, our study provides encouraging evidence that a short-term induction therapy with a TNF inhibitor plus MTX can yield long-term benefit in a considerable proportion of patients with early arthritis, even after cessation of all therapy. In contrast, the data presented indicate that MTX alone will not produce responses that are maintained over time. Placebo or supportive treatment alone neither improves nor reverses disease; these findings represent further evidence that spontaneous remission is rare once the signs and symptoms of RA have emerged. While the current study involves only TNF as a target of biological therapy, the data nevertheless strongly support the possibility that patients with early inflammatory arthritis may have a window of opportunity in which disease reversal is possible.
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